Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Mallinckrodt
McKesson
McKinsey

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,706,681

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,706,681 protect, and when does it expire?

Patent 6,706,681 protects OVIDREL and is included in one NDA.

This patent has eighteen patent family members in fourteen countries.

Summary for Patent: 6,706,681
Title: HCG liquid formulations
Abstract:The invention refers to liquid pharmaceutical compositions containing hCG stabilised with a polyalcohol or a non-reducing sugar. Preferably, the compositions are stabilised with mannitol. In the preferred embodiments such compositions are aqueous solutions in a phosphate buffer at pH 7. Such compositions are ready to be injected and, therefore, the step of reconstitution of the lyophilised powder is avoided, thus simplifying the way of use.
Inventor(s): Samaritani; Fabrizio (Rome, IT), Natale; Patrizia (Rome, IT)
Assignee: Applied Research System ARS Holding N.V. (Antilles, NL)
Application Number:08/913,748
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Drugs Protected by US Patent 6,706,681

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,706,681

PCT Information
PCT FiledMarch 21, 1997PCT Application Number:PCT/EP95/01055
PCT Publication Date:September 26, 1996PCT Publication Number: WO96/29095

International Family Members for US Patent 6,706,681

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 209930   Start Trial
Australia 2110695   Start Trial
Australia 707796   Start Trial
Brazil 9510567   Start Trial
Germany 69524456   Start Trial
Denmark 0814841   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Boehringer Ingelheim
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.